EU/3/20/2356

Table of contents

About

On 13 November 2020, orphan designation EU/3/20/2356 was granted by the European Commission to Clinical Technology Centre (Ireland) Limited, Ireland, for autologous CD34+ cells transduced ex vivo with a lentiviral vector containing a modified gamma-globin gene (also known as ARU-1801) for the treatment of sickle cell disease.

Key facts

Active substance
Autologous CD34+ cells transduced ex vivo with a lentiviral vector containing a modified gamma-globin gene
Disease / condition
Treatment of sickle cell disease
Date of first decision
13/11/2020
Outcome
Positive
EU designation number
EU/3/20/2356

Sponsor's contact details

Clinical Technology Centre (Ireland) Limited
Building C
Business & Technology Park
Garrycastle
Athlone N37 TE84
Co. Westmeath
Ireland
Tel: +15515792966
E-mail: joseph.mcintosh@aruvant.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating